A complete solution for rapid diagnostics of coronavirus infection
With its two complementary platform technologies Amplidiag® and Novodiag®, Mobidiag has the capacity to meet the needs of clinical laboratories and multiple healthcare settings. Currently on the market, these platforms combine high quality and affordable costs, allowing widespread use both in mass screening and on-demand highly targeted or syndromic tests for various infectious diseases. The extremely versatile product offer, the flexibility of the technologies used, and the expertise of the Mobidiag team allow great responsiveness in the development of new products in emergency situations. Solutions offered by Mobidiag in the case of the coronavirus pandemic is a perfect example.
Choose the right coronavirus test based on your needs
| Anti-SARS-CoV-2 Rapid Test* | Novodiag® COVID-19 | Amplidiag® COVID-19 | |
| Product no. | RTA0203 | NVD-CV-012 | AD-CV-864 |
| Package size | 50 cassettes | 12 cartridges | 864 tests |
| Sample type | Human serum, plasma or whole blood | Nasopharyngeal swab | Nasopharyngeal swab |
| Technology | Immunology | RT-PCR | RT-PCR |
| Targets | SARS-CoV-2 antibodies (IgM and/or IgG) | SARS-CoV-2 (orf1ab) SARS-CoV-2 (N) |
SARS-CoV-2 (orf1ab) SARS-CoV-2 (N) |
| Time to results | < 15min | About 1h | 45min for amplification <3h when using Amplidiag® Easy platform |
| Benefits | Fast Easy to use Can detect acute and late infections from previous infections |
Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses On demand testing Fast Easy to use Fully automated Low hands-on time (<5min) Closed system ensuring healthcare professionals's safety |
Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses Large volumes on batches Automated process for DNA extraction and PCR set up with Amplidiag® Easy platform |
| Availability | CE-IVD | Now available in Finland, France and Sweden (coming soon in UK, CE-IVD ongoing) | Now available in Finland, France and Sweden (coming soon in UK, CE-IVD ongoing) |
*Manufactured by Autobio Diagnostics, Mobidiag key partner and market leading Chinese clinical diagnostics company
Mobidiag offers 2 complementary molecular tests : Novodiag® COVID-19 and Amplidiag® COVID-19 . To provide optimal performance, both of these molecular assays have been designed using dual targets of SARS-CoV-2 (orf1ab & N genes) to include at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
Amplidiag® COVID-19 and Novodiag® COVID-19 are now available as in Finland, France and Sweden (coming soon in UK). Please contact us for more information.
In addition, Mobidiag is distributing an antibody test, the Anti-SARS-CoV-2 Rapid Test, making it one the most complete solution for rapid diagnostics of coronavirus infection on the market. This immunoassay allows detection of IgG and IgM from human serum, whole blood or plasma in about 15 minutes. Manufactured by Autobio Diagnostics, Mobidiag key partner and leading clinical diagnostics company in the Chinese the market, the Anti-SARS-CoV-2 test is now available through Mobidiag sales channels as well as our local distributors (except in Portugal, the Netherlands and Ukraine).
⊗ Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
Key Advantages
- A complete solution for rapid diagnostics of coronavirus infection
- A test for all sample volumes
- Discriminate between acute, late or past infections
- Self-sufficient in production and securing of raw materials to ensure continuity of testing throughout the complete workflow, from sample collection to results
Dedicated tests
Anti-SARS-CoV-2 Rapid Test
CE-IVD. For in vitro diagnostic use.
The immunoassay Anti-SARS-CoV-2 Rapid Test (manufactured by Autobio Diagnostics) is based on a colloidal gold method for the rapid, qualitative determination of Anti-SARS-CoV-2 (IgG/IgM antibodies of Severe Acute Respiratory Syndrome Coronavirus 2) in human serum, plasma or whole blood.
This assay is based upon one-step capture method. It contains a membrane, which is pre-coated with two mouse anti-human monoclonal antibodies (anti-IgG and anti-IgM) on two separated test lines.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
- Anti-SARS-CoV-2 (IgG and/or IgM antibodies)
- Positive agreement rate: 97.4%
- Negative agreement rate: 96.2%
- CE-IVD. For in vitro diagnostic use.
- Product no: RTA0203
- Package size: 50 cassettes
- Sample type: human serum, plasma or whole blood
- Time to result: < 15min
- Discriminate acute or recovery stage from recurrent infection
- Fast and easy to use
- Flexibility in sample type (human serum, plasma or whole blood)
- Shipping and storage at room temperature
- May 2020,
Evaluation of nine commercial SARS-CoV-2 immunoassays,
Ria Lassaunière, Anders Frische, Anders Fomsgaard, Charlotte S. Jørgensen Department of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Denmark, Zitta B. Harboe Department of Infectious Diseases and Pulmonary Medicine, Nordsjællands Hospital, Copenhagen University Hospital, Denmark, Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark, Alex C.Y. Nielsen Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark, Karen A. Krogfelt Department of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Denmark, Department of Molecular and Medicinal Biology, Institute for Science and Environment, Roskilde University, Denmark.
See full publication
Novodiag® COVID-19
Now available in Finland, France and Sweden (coming soon in UK).
Novodiag® COVID-19 test operates using the rapid ‘sample-in, result-out’ Novodiag® system, allowing the rapid detection of novel coronavirus in about 1 hour.
This fully automated solution protects laboratory staff from potential contamination. With its user-friendly nature, the Novodiag® COVID-19 solution can be delivered to and will be targeted for use in high risk and hard to reach areas without the need for highly trained personnel.
This qualitative real-time RT-PCR test will support decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
- SARS-CoV-2 (orf1ab)
- SARS-CoV-2 (N)
Novodiag® COVID-19 detects 2 molecular targets including at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
Now available in Finland, France and Sweden (coming soon in UK)
- Product no: NVD-CV-012
- Package size: 12 Test Cartridges
- Sample type: Nasopharyngeal sample
- Time to result: about 1 hour
Compatibility
- Cartridge compatible with the Novodiag® instrument
- Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses
- Single and ready to use test cartridge containing everything necessary to perform the assay
- On demand testing
- Real-time RT-PCR technology
- Internal cellularity control
- Easy to use and interpret
- Results in approx. 1h
- Easily disposable
- Shipping and storage at room temperature
- Coming soon
Amplidiag® COVID-19
Now available in Finland, France and Sweden (coming soon in UK).
Amplidiag® COVID-19 test allows the rapid detection of novel coronavirus. By allowing rapid and reliable detection of this novel coronavirus, this qualitative real-time RT-PCR test supports decisions to manage efficiently epidemiological and infection control measures, isolate patients in a timely manner and improve patient care globally.
Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Based on your location, follow the recommended process if you believe you could be infected by SARS-CoV-2.
- SARS-CoV-2 (orf1ab)
- SARS-CoV-2 (N)
Amplidiag® COVID-19 detects 2 molecular targets including at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses.
Now available in Finland, France and Sweden (coming soon in UK)
- Product no: AD-CV-864
- Package size: 864 tests
- Product format: Amplification kit for multiplex RT-PCR
- Sample material: RNA extracted from nasopharyngeal sample
- Two molecular targets to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronaviruses
- Large volumes on batches
- Runs on multiplex RT-PCR technology for optimal performance
- Automated and easy result analysis with Amplidiag® Analyzer software
- Workflow automation possible with Amplidiag® Easy:
- Automated process for DNA extraction and PCR set up
- Streamline your laboratory process and sample flow
- Optimize your sample screening process
- Report same-day results (48 samples in <3h turnaround time)
- Coming soon